Search

Your search keyword '"Albarrán, Víctor"' showing total 16 results
Start Over Author "Albarrán, Víctor"
16 results on '"Albarrán, Víctor"'

1. Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent

Author

Albarrán, Víctor, Guerrero, Patricia, de Quevedo, Coral García, González, Carlos, Chamorro, Jesús, Rosero, Diana Isabel, Moreno, Jaime, Calvo, Juan Carlos, de Aguado, Patricia Pérez, Alía, Víctor, Sotoca, Pilar, Barrill, Ana María, Román, María San, Álvarez-Ballesteros, Pablo, Serrano, Juan José, Soria, Ainara, Olmedo, María Eugenia, Saavedra, Cristina, Cortés, Alfonso, Gómez, Ana, Lage, Yolanda, Ruiz, Álvaro, Ferreiro, María Reyes, Longo, Federico, Garrido, Pilar, and Gajate, Pablo

Published
2024
Full Text
View/download PDF

2. Negative impact of steroids on the efficacy of immunotherapy in a multi- tumor cohort: time and dose-dependent

Author

Albarrán, Víctor, primary, Guerrero, Patricia, additional, de Quevedo, Coral García, additional, González, Carlos, additional, Chamorro, Jesús, additional, Rosero, Diana Isabel, additional, Moreno, Jaime, additional, Calvo, Juan Carlos, additional, de Aguado, Patricia Pérez, additional, Alía, Víctor, additional, Sotoca, Pilar, additional, Barrill, Ana María, additional, Román, María San, additional, Álvarez-Ballesteros, Pablo, additional, Serrano, Juan José, additional, Soria, Ainara, additional, Olmedo, María Eugenia, additional, Saavedra, Cristina, additional, Cortés, Alfonso, additional, Gómez, Ana, additional, Lage, Yolanda, additional, Ruiz, Álvaro, additional, Ferreiro, María Reyes, additional, Longo, Federico, additional, Garrido, Pilar, additional, and Gajate, Pablo, additional

Published
2024
Full Text
View/download PDF

3. Adoptive T cell therapy for solid tumors: current landscape and future challenges

Author

Albarrán, Víctor, primary, San Román, María, additional, Pozas, Javier, additional, Chamorro, Jesús, additional, Rosero, Diana Isabel, additional, Guerrero, Patricia, additional, Calvo, Juan Carlos, additional, González, Carlos, additional, García de Quevedo, Coral, additional, Pérez de Aguado, Patricia, additional, Moreno, Jaime, additional, Cortés, Alfonso, additional, and Soria, Ainara, additional

Published
2024
Full Text
View/download PDF

4. BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature

Author

Guerrero, Patricia, primary, Albarrán, Víctor, additional, San Román, María, additional, González-Merino, Carlos, additional, García de Quevedo, Coral, additional, Moreno, Jaime, additional, Calvo, Juan Carlos, additional, González, Guillermo, additional, Orejana, Inmaculada, additional, Chamorro, Jesús, additional, Martínez-Delfrade, Íñigo, additional, Morón, Blanca, additional, de Frutos, Belén, additional, and Ferreiro, María Reyes, additional

Published
2023
Full Text
View/download PDF

5. Recurrent Glioblastoma: A Review of the Treatment Options

Author

Vaz-Salgado, Maria Angeles, primary, Villamayor, María, additional, Albarrán, Víctor, additional, Alía, Víctor, additional, Sotoca, Pilar, additional, Chamorro, Jesús, additional, Rosero, Diana, additional, Barrill, Ana M., additional, Martín, Mercedes, additional, Fernandez, Eva, additional, Gutierrez, José Antonio, additional, Rojas-Medina, Luis Mariano, additional, and Ley, Luis, additional

Published
2023
Full Text
View/download PDF

6. Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature

Author

Albarrán, Víctor, primary, Chamorro, Jesús, additional, Pozas, Javier, additional, San Román, María, additional, Rosero, Diana Isabel, additional, Saavedra, Cristina, additional, Gion, María, additional, Cortés, Alfonso, additional, Escalera, Elena, additional, Guerra, Eva, additional, López Miranda, Elena, additional, Fernández Abad, María, additional, and Martínez Jañez, Noelia, additional

Published
2023
Full Text
View/download PDF

7. Current Landscape of Immunotherapy for Advanced Sarcoma

Author

Albarrán, Víctor, primary, Villamayor, María Luisa, additional, Pozas, Javier, additional, Chamorro, Jesús, additional, Rosero, Diana Isabel, additional, San Román, María, additional, Guerrero, Patricia, additional, Pérez de Aguado, Patricia, additional, Calvo, Juan Carlos, additional, García de Quevedo, Coral, additional, González, Carlos, additional, and Vaz, María Ángeles, additional

Published
2023
Full Text
View/download PDF

8. Spinal Intramedullary Ewing Sarcoma with Meningeal Carcinomatosis: A Complete Response to Chemotherapy and Neuroaxis Irradiation. Case Report and Review of Literature

Author

Albarrán, Víctor, primary, Villamayor, María Luisa, additional, Ruz, Ignacio, additional, Chamorro, Jesús, additional, Rosero, Diana Isabel, additional, Pozas, Javier, additional, Román, María San, additional, Ballesteros, Pablo Álvarez, additional, and Ángeles Vaz, María, additional

Published
2023
Full Text
View/download PDF

9. Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas

Author

Albarrán, Víctor, primary, Villamayor, María Luisa, additional, Chamorro, Jesús, additional, Rosero, Diana Isabel, additional, Pozas, Javier, additional, San Román, María, additional, Calvo, Juan Carlos, additional, Pérez de Aguado, Patricia, additional, Moreno, Jaime, additional, Guerrero, Patricia, additional, González, Carlos, additional, García de Quevedo, Coral, additional, Álvarez-Ballesteros, Pablo, additional, and Vaz, María Ángeles, additional

Published
2022
Full Text
View/download PDF

10. Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates

Author

Albarrán, Víctor, primary, Rosero, Diana Isabel, additional, Chamorro, Jesús, additional, Pozas, Javier, additional, San Román, María, additional, Barrill, Ana María, additional, Alía, Víctor, additional, Sotoca, Pilar, additional, Guerrero, Patricia, additional, Calvo, Juan Carlos, additional, Orejana, Inmaculada, additional, Pérez de Aguado, Patricia, additional, and Gajate, Pablo, additional

Published
2022
Full Text
View/download PDF

12. Management of Intracranial Metastases in EGFR-Mutated NSCLC: A Review of Literature following an Unusual Case Report

Author

Albarrán, Víctor, Pozas, Javier, José Soto, Juan, Esteban, Jorge, Corral, Elena, Lage, Yolanda, Gajate, Pablo, and Garrido, Pilar

Subjects
Article Subject, respiratory tract diseases
Abstract

The arrival of subsequent generations of tyrosine-kinase inhibitors (TKIs) has significantly broaden the EGFR-mutated lung cancer therapeutic landscape. Results from the FLAURA clinical trial have pushed osimertinib to the first-line treatment for patients with advanced-stage disease, showing outstanding control rates of intracranial metastases, considerably higher than those of the first and second-generation EGFR TKIs. A progressively better knowledge of short and long-term neurocognitive side effects of radiotherapy, as well as the lack of evidence about the benefit of its combination with TKIs, has opened a debate about its indication at diagnosis of intracranial disease, at least before the response to targeted therapy has been evaluated. However, there is a small percentage of primarily resistant cases to osimertinib, mainly due to histologic transformation, acquired EGFR mutations and off-target genetic resistances that lead to a scenery of poor clinical prognosis in which radiotherapy may have a higher relevance for the management of brain metastases. We offer a review of the current recommendations for the management of intracranial metastases in EGFR-mutated NSCLC and the resistance mechanisms to third-generation TKIs, following the report of an unusual clinical case with a rapid progression to osimertinib.

Published
2021
Full Text
View/download PDF

14. P3.02c-079 Immunotherapy in Non-Small Cell Lung Cancer (NSCLC): Biomarkers Associated with Early Death: Topic: IT Biomarkers

Author

Del Toro, Jacobo Muñoz, Olmedo, Eugenia, Gomez, Ana, Madariaga, Ainhoa, Templado, Josefa Perez, Gorospe, Luis, Reguera, Pablo, Soria, Ainara, Gión, María, Martínez, Olga, Molina, Javier, Villamayor, María, Saavedra, Cristina, Muñoz, Gema, Albarrán, Victor, Benito, Amparo, Barquin, Arantzazu, Cabañero, Alberto, Alonso, Teresa, Gajate, Pablo, Grande, Enrique, and Garrido, Pilar

Published
2017
Full Text
View/download PDF

15. P3.02c-075 Could Blood Levels of Lymphocytes and Eosinophils Help Us to Identify the Efficacy or Toxicity of Immunotherapy?: Topic: IT Biomarkers

Author

Olmedo, Eugenia, Del Toro, Jacobo Muñoz, Gorospe, Luis, Templado, Josefa Perez, Gomez, Ana, Reguera, Pablo, Gión, María, Madariaga, Ainhoa, Martínez, Olga, Molina, Javier, Villamayor, María, Albarrán, Victor, Barquin, Arantzazu, Saavedra, Cristina, Soria, Ainara, Alonso, Teresa, Gajate, Pablo, Grande, Enrique, and Garrido, Pilar

Published
2017
Full Text
View/download PDF

16. Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients.

Author

Guerrero P, Albarrán V, González-Merino C, García de Quevedo C, Sotoca P, Chamorro J, Rosero DI, Barrill A, Alía V, Calvo JC, Moreno J, Pérez de Aguado P, Álvarez-Ballesteros P, San Román M, Serrano JJ, Soria A, Olmedo ME, Saavedra C, Cortés A, Gómez A, Lage Y, Ruiz Á, Ferreiro MR, Longo F, Guerra E, Martínez-Delfrade Í, Garrido P, and Gajate P

Abstract

Background: Immune checkpoint inhibitors (ICI) have changed the therapeutic landscape of many solid tumors. Modulation of the intestinal microbiota by antibiotics (Abx) has been suggested to impact on ICI outcomes., Methods: Retrospective analysis of 475 patients with advanced solid tumors treated with ICI from 2015 to 2022. For each patient, the use of Abx was recorded from 1 month before ICI initiation until disease progression or death. The impact of Abx on objective response rates (ORR), disease control rates (DCR), progression-free survival (PFS), and overall survival (OS) was analyzed. Kaplan-Meier and log-rank tests were used to compare survival outcomes., Results: In total 475 patients with advanced solid tumors were evaluated. Median age was 67.5 years and performance status (PS) was 0-1 in 84.6%. 66.5% of patients received Abx during treatment with ICI, mainly beta-lactams (53.8%) and quinolones (35.9%). The early exposure to Abx (from 60 days before to 42 days after the first cycle of ICI) was associated with a lower ORR (27.4% vs 39.4%; P < .01), a lower DCR (37.3% vs 57.4%; P < .001), lower PFS (16.8 m vs 27.8 m; HR 0.66; P < .001]) and lower OS (2.5 m vs 6.6 m; HR 0.68; P = .001]). The negative impact of Abx on OS and PFS was confirmed by a multivariable analysis. This effect was not observed among patients receiving Abx after 6 weeks from ICI initiation., Conclusions: Our results validate the hypothesis of a detrimental effect of an early exposure to Abxon the efficacy of ICI in a multi-tumor cohort of patients., (© The Author(s) 2024. Published by Oxford University Press.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results